SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
sc-12-0775_sm_SupplFigure1.pdf315KFigure S1, related to Figure 1. FoxM1 immunohistochemistry. Immunohistochemistry for FoxM1 (green) and Tuj1 (red) in mouse brains of embryonic day 17.
sc-12-0775_sm_SupplFigure2.pdf101KFigure S2, related to Figure 1. FoxM1 regulates neural progenitor proliferation. (A)Quantitative RT-PCR analysis of FoxM1b in E17 neurospheres overexpressing FoxM1 (isoforms b) or EGFP (control) (N=3). (B) Left panel representing FoxM1 mRNA expression in E17 neurospheres after transfection with siRNA for either mock, FoxM1a, or FoxM1a/b. The numbers indicate the cycles of PCR reaction. Gapdh is used as internal control. Right panel shows picture representing siRNA treated spheres. Original magnification 10X. (C) Neurosphere forming assay with clonal density of E17 neurospheres overexpressing FoxM1 (isoforms b) or EGFP (control). Neurosphere forming assay were performed in triplicates in 96 well plate and repeated at least three times independently. Scale bars represent 100 micron. (D) Neurosphere forming assay with clonal density of E17 neurospheres after transfection with siRNA for either mock, FoxM1a, or FoxM1a/b. Neurosphere forming assay were performed in triplicates in 96 well plate and repeated at least three times independently.
sc-12-0775_sm_SupplFigure3.pdf223KFigure S3, related to Figure 2. FOXM1 in mouse GBM model. FoxM1 immunohistochemistry in non-tumor regions of Mut6 mice. Hematoxylin counterstaining is shown in blue. Original magnifications, 20X. Scale bars represent 50 micron.
sc-12-0775_sm_SupplFigure4.tif2669KFigure S4, related to Figure 2. FOXM1 in human GBM tumors. FOXM1 staining with human GBM tissues, showing nuclear FOXM1 immunoreactivity. Blue staining indicates Hematoxylin counterstaining. Original magnifications, 20X. Scale bars represent 50 micron. Similar staining pattern was observed in 5 different patient samples.
sc-12-0775_sm_SupplFigure5.pdf96KFigure S5, related to Figure 2. FOXM1 expression in GSCs. (A) Graph (upper panel) indicating the relative FOXM1 mRNA expression determined by qRT-PCR in undifferentiated GBM1600 neurospheres (GSCs) and their sister cultures in pro-differentiation condition (SPGCs). (B) Histograph (lower panel) indicating the relative FOXM1 protein expression determined by flow cytometry with the same sample set described above.
sc-12-0775_sm_SupplFigure6.pdf70KFigure S6, related to Figure 2: FOXM1 activity in GSCs. Graph indicating the FOXM1 promoter activity in GBM30 GSC vs. SPGCs cells with transfection of the 6×FOXM1 TATA–luciferase plasmid.
sc-12-0775_sm_SupplFigure7.pdf89KFigure S7, related to Figure 3. Correlation of FOXM1 and MELK expression. Evaluation of correlation of MELK and FOXM1 mRNA expression profile (Affymetrix Human Genome U133A Array) with newly-diagnosed GBM (A) (n=58) and recurrent GBM (B)(n=22).
sc-12-0775_sm_SupplFigure8.tif1346KFigure S8, related to Figure 3. Transcriptional interaction between FOXM1 and MELK. (A) RT-PCR demonstrating the effect of overexpression of FOXM1, MELK, or GFP (control) on mRNA expression of FOXM1 and MELK. GAPDH is used as internal control. (N=3)
sc-12-0775_sm_SupplFigure9.pdf62KFigure S9, related to Figure 3. Abundance of GFP protein in MELK immunoprecipitated HEK 293 cells after transfection of the plasmids encoding Empty-Flag, MELK-Flag, and MELK D150A-Flag.
sc-12-0775_sm_SupplFigure10.pdf444KFigure S10, related to Figure 7. Slice cultures of GBM surgical tissues. Representative H&E staining of a slice culture of GBM surgical tissue treated with DMSO for 72 hours, exhibiting the preservation of the cytoarchitecture of tumors in this assay. Original magnifications, 10X Scale bar represents 100 micron.
sc-12-0775_sm_SupplFigure11.pdf339KFigure S11, related to Figure 7. Effect of Siomycin A on GBM slice cultures. Effect of Temozolomide (TMZ) or Siomycin A (SM) treatment on cell survival and proliferation using the slice cultures of GBM surgical tissues. Experiment was repeated suing four different patient samples.
sc-12-0775_sm_SupplInfor.pdf98KSupplementary Data

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.